Andrew B. Cubitt
Corporate Officer/Principal at ATYR PHARMA, INC.
Profile
Dr. Andrew B.
Cubitt is a Vice President-External Scientific Alliances at aTyr Pharma, Inc. Dr. Cubitt was previously employed as an Executive Director-Corporate Development by AnaptysBio, Inc., an Associate Director-Intellectual Property by X-Ceptor Therapeutics, Inc., a Senior Manager-Technology & Intellectual Property by Aurora Biosciences Corp., and a Director-Intellectual Property by Ambit Biosciences Corp.
He received his undergraduate degree from the University of Birmingham and a doctorate degree from The University of Sheffield.
Andrew B. Cubitt active positions
| Companies | Position | Start |
|---|---|---|
| ATYR PHARMA, INC. | Corporate Officer/Principal | 2011-08-31 |
Former positions of Andrew B. Cubitt
| Companies | Position | End |
|---|---|---|
| ANAPTYSBIO, INC. | Founder | 2009-06-30 |
Aurora Biosciences Corp.
 Aurora Biosciences Corp. BiotechnologyHealth Technology Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA. | Corporate Officer/Principal | 2001-12-31 |
| AMBIT BIOSCIENCES CORP | Corporate Officer/Principal | - |
X-Ceptor Therapeutics, Inc.
 X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | - |
Training of Andrew B. Cubitt
| University of Birmingham | Undergraduate Degree |
| The University of Sheffield | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ATYR PHARMA, INC. | Health Technology |
| ANAPTYSBIO, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Aurora Biosciences Corp.
Aurora Biosciences Corp. BiotechnologyHealth Technology Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA. | Health Technology |
Ambit Biosciences Corp.
 Ambit Biosciences Corp. Pharmaceuticals: MajorHealth Technology Ambit Biosciences Corp. develops pharmaceutical drugs. It engages in discovery, development and commercialization of small-molecule kinase inhibitors for the treatment of cancer. The firm provides drug to treat unmet medical needs in oncology, autoimmune and inflammatory diseases. The company was founded on May 17, 2000 and is headquartered in San Diego, CA. | Health Technology |
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
- Stock Market
- Insiders
- Andrew B. Cubitt
